Project: Development of a novel microbiota-based therapy for the prevention of type 2 diabetes mellitus.

Acronym PROMISE (Reference Number: 12091)
Duration 01/05/2018
Project Topic PROMISE will deliver an innovative microbiota-based therapy based upon the anaerobic human derived butyrate-producing bacterium Eubacterium hallii, for the reduction of insulin resistance and prevention of type 2 diabetes mellitus (T2DM) in individuals suffering from metabolic syndrome (MetS). Additionally, this project adopts a novel approach aiming to set new standards in performing (pre)clinical studies using a microbial therapy in stratified target groups.
Network Eurostars 2
Call Eurostars Cut-Off 8

Project partner

Number Name Role Country
1 Caelus Pharmaceuticals B.V. Coordinator Netherlands
2 BaseClear B.V. Partner Netherlands
3 ProDigest BVBA Partner Belgium
4 Integrated BioBank of Luxembourg Partner Luxembourg